RU2012124216A - Фармацевтическая комбинация соединения простагландина и nsaid для лечения глаукомы и глазной гипертензии - Google Patents

Фармацевтическая комбинация соединения простагландина и nsaid для лечения глаукомы и глазной гипертензии Download PDF

Info

Publication number
RU2012124216A
RU2012124216A RU2012124216/15A RU2012124216A RU2012124216A RU 2012124216 A RU2012124216 A RU 2012124216A RU 2012124216/15 A RU2012124216/15 A RU 2012124216/15A RU 2012124216 A RU2012124216 A RU 2012124216A RU 2012124216 A RU2012124216 A RU 2012124216A
Authority
RU
Russia
Prior art keywords
composition
glaucoma
pharmaceutically acceptable
effective amount
treatment
Prior art date
Application number
RU2012124216/15A
Other languages
English (en)
Russian (ru)
Inventor
Раджеш Кширсагар
Чхандрашекар КАДАМ
Правин КАМБЛЕ
См Мудда
Original Assignee
Микро Лабс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микро Лабс Лимитед filed Critical Микро Лабс Лимитед
Publication of RU2012124216A publication Critical patent/RU2012124216A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2012124216/15A 2009-11-11 2010-11-01 Фармацевтическая комбинация соединения простагландина и nsaid для лечения глаукомы и глазной гипертензии RU2012124216A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2761CH2009 2009-11-11
IN2761/CHE/2009 2009-11-11
PCT/IN2010/000717 WO2011058579A1 (en) 2009-11-11 2010-11-01 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
RU2012124216A true RU2012124216A (ru) 2013-12-20

Family

ID=43587393

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012124216/15A RU2012124216A (ru) 2009-11-11 2010-11-01 Фармацевтическая комбинация соединения простагландина и nsaid для лечения глаукомы и глазной гипертензии

Country Status (10)

Country Link
US (1) US20120232140A1 (enExample)
EP (1) EP2498768A1 (enExample)
JP (1) JP2013510845A (enExample)
CN (1) CN102711748A (enExample)
AU (1) AU2010317390A1 (enExample)
BR (1) BR112012010936A2 (enExample)
CA (1) CA2780611A1 (enExample)
MX (1) MX2012005447A (enExample)
RU (1) RU2012124216A (enExample)
WO (1) WO2011058579A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852995C (en) * 2011-10-12 2016-03-29 Bausch & Lomb Incorporated Ocular composition containing bromfenac with increased bioavailability
JP6185725B2 (ja) * 2012-02-24 2017-08-23 わかもと製薬株式会社 水性医薬組成物
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent

Also Published As

Publication number Publication date
CN102711748A (zh) 2012-10-03
EP2498768A1 (en) 2012-09-19
WO2011058579A1 (en) 2011-05-19
JP2013510845A (ja) 2013-03-28
MX2012005447A (es) 2012-07-20
US20120232140A1 (en) 2012-09-13
BR112012010936A2 (pt) 2017-10-17
CA2780611A1 (en) 2011-05-19
AU2010317390A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
AU2012307812A8 (en) Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
GB2581656A (en) Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
RU2014103544A (ru) Комбинация фиксированных доз биматопроста и бримонидина
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
EA201070483A1 (ru) Новые офтальмологические композиции
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
RU2013142602A (ru) Композиции и способы для нехирургического лечения птоза
RU2013107744A (ru) Растворы биматопроста и тимолола, не содержащие консервантов
EA028008B1 (ru) Составы ингибитора lfa-1
MX2014012158A (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
RU2017118405A (ru) Новое лечение роговицы с применением ламинина
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
JP2024111298A (ja) 水性組成物その陸
US20130035338A1 (en) Eyelid treatment
JP2026021353A (ja) 保存効力又は光安定性が改善された点眼用医薬組成物
AR102283A1 (es) Conjugados de prostaglandina y derivados para tratar el glaucoma y la hipertensión ocular
CN103596572A (zh) 水性眼用组合物
JP2017534658A5 (enExample)
WO2022207979A3 (en) Heterocyclic compounds and their use
JP2020524138A (ja) 緑内障治療用点眼組成物
MX2025003934A (es) Métodos para preparar derivados de carbamato
RU2013147449A (ru) Фармацевтическая композиция для профилактики или лечения макулярной дегенерации
NZ596035A (en) METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION using 15-keto-prostaglandin such as 13,14-dihydro-15-keto-20-ethyl-prostagladin F2-alpha isopropyl ester
JP2013510845A5 (enExample)